Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
4.680
-0.580 (-11.03%)
At close: Apr 28, 2026, 4:00 PM EDT
4.825
+0.144 (3.09%)
After-hours: Apr 28, 2026, 7:49 PM EDT
Company Description
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD.
Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Dec 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Shane Schaffer |
Contact Details
Address: 1901 West 47th Place Kansas City, Kansas 66205 United States | |
| Phone | 913 942 2300 |
| Website | cingulate.com |
Stock Details
| Ticker Symbol | CING |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001862150 |
| CUSIP Number | 17248W105 |
| ISIN Number | US17248W3034 |
| Employer ID | 86-3825535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive Vice President and Chief Medical Officer |
| Jennifer L. Callahan CPA | Executive Vice President, Chief Financial Officer and Secretary |
| Nilay D. Patel J.D. | Executive Vice President, Chief Legal Officer and Chief Compliance Officer |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive Vice President and Chief Science Officer |
| Thomas Dalton | Vice President of Investor and Public Relations |
| Downey Bryan Wade | Executive Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | 424B3 | Prospectus |
| Apr 24, 2026 | EFFECT | Notice of Effectiveness |
| Apr 14, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 424B3 | Prospectus |
| Mar 26, 2026 | EFFECT | Notice of Effectiveness |
| Mar 26, 2026 | SCHEDULE 13D/A | Filing |
| Mar 24, 2026 | EFFECT | Notice of Effectiveness |
| Mar 24, 2026 | 8-K | Current Report |
| Mar 24, 2026 | 424B3 | Prospectus |